NCT05726110View on ClinicalTrials.gov

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

PHASE3RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 29, 2023

Primary Completion Date

December 10, 2024

Study Completion Date

December 31, 2024

Conditions
Relapsed or Refractory Acute Myeloid Leukemia
Interventions
DRUG

Selinexor

Given PO

DRUG

Homoharringtonine

Given per standard of care

DRUG

Daunorubicin

Given per standard of care

DRUG

Cytarabine

Given per standard of care

DRUG

Granulocyte Colony-Stimulating Factor

Given per standard of care

DRUG

Aclacinomycin

Given per standard of care

Trial Locations (1)

030000

RECRUITING

Tao Wang, Taiyuan

All Listed Sponsors
collaborator

Antengene Corporation

INDUSTRY

lead

Shanxi Bethune Hospital

OTHER